<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in the treatment of high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (20-30% blasts) has been demonstrated </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the efficacy of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in daily clinical practice and to identify predictors for response, we analysed a cohort of 90 MDS, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients who have been treated in a Dutch compassionate named patient programme </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received <z:chebi fb="0" ids="2038">azacitidine</z:chebi> for a median of five cycles (range 1-19) </plain></SENT>
<SENT sid="3" pm="."><plain>The overall response rate (complete/partial/haematological improvement) was 57% in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 53% in high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 50% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, and 39% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Median overall survival (OS) was 13·0 (9·8-16·2) months </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis confirmed circulating blasts [Hazard Ratio (HR) 0·48, 95% confidence interval (CI) 0·24-0·99; P = 0·05] and poor risk cytogenetics (HR 0·45, 95% CI 0·22-0·91; P = 0·03) as independent predictors for OS </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, this analysis also identified platelet doubling after the first cycle of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> as a simple and independent positive predictor for OS (HR 5·4, 95% CI 0·73-39·9; P = 0·10) </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, routine administration of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> to patients with variable risk groups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is feasible, and subgroups with distinct efficacy of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> treatment can be identified </plain></SENT>
</text></document>